5-Fluoro-2-vinyl-pyridine | 869108-71-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-Fluoro-2-vinyl-pyridine
• 英文别名: 5-fluoro-2-vinylpyridine；2-ethenyl-5-fluoropyridine
• CAS: 869108-71-4
• 化学式: C₇H₆FN
• 分子量: 123.13
• InChiKey: WOVNLNHLHDTSNS-UHFFFAOYSA-N

物化性质

• 沸点：
  145.2±20.0 °C(Predicted)
• 密度：
  1.091±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于二氯甲烷；乙酸乙酯

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-Fluoro-2-vinyl-pyridine 在 Grubbs catalyst first generation 、 lithium aluminium tetrahydride 作用下， 以 乙醚 、 正己烷 、 二氯甲烷 为溶剂， 反应 21.5h， 生成
  参考文献：
  名称：

  The Least Stable Isomer of BN Naphthalene: Toward Predictive Trends for the Optoelectronic Properties of BN Acenes

  摘要：

  The least stable isomer of the parental BN naphthalene series has been synthesized in a simple four-step sequence. Its experimental electronic structure characterization via UV-PES, cyclic voltammetry, and UV-vis spectroscopy in direct comparison with three other known BN naphthalene isomers has established two guiding principles for predicting the electronic structures of BN acene compounds: (1) Orientational BN isomers have similar HOMO-LUMO gaps. (2) For each pair of orientational BN isomers, the more thermodynamically stable compound has the lower HOMO energy. Furthermore, we demonstrate that BN/CC isosterism in the context of BN-9,1-Naph can impact crystal packing to favor a cofacial pi-stack motif.

  DOI：

  10.1021/jacs.7b02661
• 作为产物：
  描述：

  2-溴-5-氟吡啶 、 trivinylindium 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 以51%的产率得到5-Fluoro-2-vinyl-pyridine
  参考文献：
  名称：

  The Least Stable Isomer of BN Naphthalene: Toward Predictive Trends for the Optoelectronic Properties of BN Acenes

  摘要：

  The least stable isomer of the parental BN naphthalene series has been synthesized in a simple four-step sequence. Its experimental electronic structure characterization via UV-PES, cyclic voltammetry, and UV-vis spectroscopy in direct comparison with three other known BN naphthalene isomers has established two guiding principles for predicting the electronic structures of BN acene compounds: (1) Orientational BN isomers have similar HOMO-LUMO gaps. (2) For each pair of orientational BN isomers, the more thermodynamically stable compound has the lower HOMO energy. Furthermore, we demonstrate that BN/CC isosterism in the context of BN-9,1-Naph can impact crystal packing to favor a cofacial pi-stack motif.

  DOI：

  10.1021/jacs.7b02661

文献信息

• HETEROAROMATIC MONOAMIDES AS OREXININ RECEPTOR ANTAGONISTS
  申请人：Knust Henner

  公开号：US20090312314A1

  公开（公告）日：2009-12-17

  The present invention is concerned with novel sulfonamides of formula wherein R 1 , R 2 , R 3 , R 4 , R 5 , Ar, Ar 1 , Ar 2 , n, o and p are as described in the description and claims. The compounds are orexin receptor antagonists that may be useful in the treatment of disorders, in which orexin pathways are involved.

  本发明涉及一种新型的磺胺类化合物，其化学式如下： 其中R1、R2、R3、R4、R5、Ar、Ar1、Ar2、n、o和p如描述和声明中所述。这些化合物是俄雷欣受体拮抗剂，可能在涉及俄雷欣途径的疾病治疗中有用。
• [EN] PYRIMIDINE PDE10 INHIBITORS<br/>[FR] INHIBITEURS PYRIMIDINES DE PDE10
  申请人：MERCK SHARP & DOHME

  公开号：WO2013028590A1

  公开（公告）日：2013-02-28

  The present invention is directed to pyrimidine compounds which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及嘧啶化合物，其可用作治疗与磷酸二酯酶10（PDE10）相关的中枢神经系统疾病的治疗剂。本发明还涉及利用这些化合物治疗神经系统和精神疾病，如精神分裂症、精神病或亨廷顿病，以及与纹状体功能不足或基底神经节功能障碍相关的疾病。
• Imidazopyridine Compound
  申请人：Sakuraba Shunji

  公开号：US20070249659A1

  公开（公告）日：2007-10-25

  The present invention provides an imidazopyridine compound represented by formula (I), wherein R 1 and R 2 each independently represent a C 1-6 alkyl group et al; R 3 and R 4 each independently represent a hydrogen atom, a methyl et al; Ar 1 is a divalent substituent representing a monocyclic or bicyclic, 3- to 8-membered aromatic or aliphatic heterocyclic group et al; Ar 2 represents an aromatic carbocyclic group, or an aromatic heterocyclic group; W represents —(CH 2 ) m et al, and m indicates an integer of from 0 to 10. This compound acts as a melanin concentrating hormone receptor antagonist, and is useful as treating agents for obesity.

  本发明提供了一种以式（I）表示的咪唑吡啶化合物，其中R1和R2各自独立地表示C1-6烷基等；R3和R4各自独立地表示氢原子、甲基等；Ar1表示一个双价的取代基，该取代基代表一个单环或双环、3-到8-成员的芳香或脂肪族杂环基等；Ar2表示一个芳香碳环基或芳香杂环基；W表示—（CH2）me等，其中m表示从0到10的整数。该化合物作为黑色素浓集激素受体拮抗剂，并且可用作肥胖症的治疗剂。
• Heteroaromatic monoamides as orexinin receptor antagonists
  申请人：Hoffmann-La Roche Inc.

  公开号：US08133909B2

  公开（公告）日：2012-03-13

  The present invention is concerned with novel sulfonamides of formula wherein R1, R2, R3, R4, R5, Ar, Ar1, Ar2, n, o and p are as described in the description and claims. The compounds are orexin receptor antagonists that may be useful in the treatment of disorders, in which orexin pathways are involved.

  本发明涉及新型磺胺类化合物，其化学式为其中R1，R2，R3，R4，R5，Ar，Ar1，Ar2，n，o和p如说明书和权利要求中所述。这些化合物是促进睡眠的药物，可用于治疗与促进睡眠通路有关的疾病。
• ARYLOXMETHYL CYCLOPROPANE DERIVATIVES AS PDE10 INHIBITORS
  申请人：Breslin Michael J.

  公开号：US20140336195A1

  公开（公告）日：2014-11-13

  The present invention is directed to aryloxymethyl cyclopropane derivatives which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及芳氧甲基环丙烷衍生物，其可用作治疗与磷酸二酯酶10（PDE10）相关的中枢神经系统疾病的治疗剂。本发明还涉及使用这些化合物治疗神经系统和精神疾病，如精神分裂症、精神病或亨廷顿病等与纹状体低功能或基底节功能障碍有关的疾病。